drugset / Trial / NCT03169777

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

NCT03169777

Phase 1/2 Withdrawn ImmunityBio, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with recurrent and metastatic CRC.

Timeline

Start
2018-08
Primary completion
2019-01
Completion
2021-12-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Avelumab Monoclonal antibody
Subject Bevacizumab Monoclonal antibody
Subject Capecitabine Small molecule
Subject Cetuximab Monoclonal antibody
Subject Cyclophosphamide Other / unclassified
Subject ETBX-011 Vaccine
Subject ETBX-021 Vaccine
Subject ETBX-051 Vaccine
Subject ETBX-061 Vaccine
Subject Fulvestrant Small molecule
Subject GI-4000 Vaccine
Subject GI-6207 Vaccine
Subject GI-6301 Vaccine
Subject Leucovorin Small molecule
Subject Lovaza Other / unclassified
Subject N-803 Protein / enzyme biologic
Subject Nivolumab Monoclonal antibody
Subject Oxaliplatin Small molecule
Subject Paclitaxel Small molecule
Subject fluorouracil Small molecule
Subject haNK Cell therapy Intravenous

Indications